Business

Mass. Movers

Curis takes on $30 million worth of debt

Advertisement

Curis Inc., a Lexington company developing small-molecule cancer drugs, said it will enter into a $30 million debt transaction, secured with certain future Erivedge royalties, with an investment fund managed by Pharmakon Advisors. Erivedge is the first and only US-approved medicine for people with advanced basal cell carcinoma, a press release said. It is developed and marketed by Genentech. The royalty payments that Curis will be entitled to under a collaboration with Genentech will be the source of funds to repay the loan.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com